Clarity Peptide Imaging services

Clarity’s Mission


At Clarity, our mission is to develop innovative radiopharmaceutical products and offer seamless preclinical to clinical imaging services that ensure better patient outcomes.


Clarity is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.

Clarity’s platform technology allows antibodies to be radiolabeled and visualised using PET imaging. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach to therapy by only treating those patients that are likely to respond to therapy and excluding those that won’t respond to therapy. This precision medicine approach is at the forefront of drug development.

Find out more
pharmaceutical development

Pharmaceutical Development


Clarity develops personalised medicine diagnostic imaging and therapeutic products. By using its proprietary technology, Clarity is developing next generation theranostic solutions for serious diseases, such as cancer, that are not well treated by current therapies.


Clarity Pharmaceuticals actively manages an in-house drug development program, with its first drug SARTATE™, an oncology theranostic (diagnostic and therapy), in clinical trials for neuroendocrine tumours. This new agent will also potentially allow better treatment of paediatric cancers and is entering clinical trials for neuroblastoma in 2017. Clarity is in a number of negotiations to expand its program and tap into new markets that can be better served with our SAR technology. As such, the prostate cancer market remains a key focus for the Company. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current technologies. Clarity is also in early preclinical development with a small range of other therapies for a broad range of cancers.

Find out more
imaging services

Antibody and Peptide Imaging Services


Clarity Pharmaceuticals offers it’s imaging services to groups with antibodies and peptides in development.


Imaging biopharmaceuticals in early stage development allows developers to visualise where their antibody or peptide is going, including targeting, off-target binding, clearance and biodistribution. This de-risks the development process, and allows companies to make early decisions about their antibody and peptide drug candidates.

antibody imaging service
peptide imaging service
imaging services
Find out more